
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>Page 84 of 119</i></p>
<p style="font-size: small; color: grey;"><i>Abbott_Laboratories_10k_084.pdf</i></p>
<p>Abbott Laboratories and Subsidiaries Notes to Consolidated Financial Statements (Continued)</p>
<h2>Note 13 - Post-Employment Benefits (Continued)</h2>
<p>The following table summarizes the basis used to measure the defined benefit and medical and dental plan assets at fair value:</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th rowspan="2">Outstanding Balances</th>
		<th colspan="4">Basis of Fair Value Measurement</th>
	</tr>
	<tr>
		<th>Quoted Prices in Active Markets</th>
		<th>Significant Other Observable Inputs</th>
		<th>Significant Unobservable Inputs</th>
		<th>Measured at NAV (k)</th>
	</tr>
	<tr>
		<td></td>
		<td colspan="5">(in millions)</td>
	</tr>
	<tr>
		<td>December 31, 2017:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Equities:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>U.S. large cap (a)</td>
		<td>$ 2,506</td>
		<td>$ 1,600</td>
		<td>$ —
</td>
		<td>$ —
</td>
		<td>$ 906</td>
	</tr>
	<tr>
		<td>U.S. mid and small cap (b)</td>
		<td>670</td>
		<td>243</td>
		<td>—
</td>
		<td>—
</td>
		<td>427</td>
	</tr>
	<tr>
		<td>International (c)</td>
		<td>1,937</td>
		<td>448</td>
		<td>—
</td>
		<td>—
</td>
		<td>1,489</td>
	</tr>
	<tr>
		<td>Fixed income securities:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>U.S. government securities (d)</td>
		<td>510</td>
		<td>11</td>
		<td>286</td>
		<td>—</td>
		<td>213</td>
	</tr>
	<tr>
		<td>Corporate debt instruments (e)</td>
		<td>930</td>
		<td>107</td>
		<td>411</td>
		<td>—
</td>
		<td>412</td>
	</tr>
	<tr>
		<td>Non-U.S. government securities (f)</td>
		<td>625</td>
		<td>222</td>
		<td>—</td>
		<td>—
</td>
		<td>403</td>
	</tr>
	<tr>
		<td>Other (g)</td>
		<td>216</td>
		<td>93</td>
		<td>27</td>
		<td>—
</td>
		<td>96</td>
	</tr>
	<tr>
		<td>Absolute return funds (h)</td>
		<td>1,814</td>
		<td>135</td>
		<td>—</td>
		<td>—
</td>
		<td>1,679</td>
	</tr>
	<tr>
		<td>Commodities (i)</td>
		<td>60</td>
		<td>—</td>
		<td>—</td>
		<td>4</td>
		<td>56</td>
	</tr>
	<tr>
		<td>Cash and Cash Equivalents</td>
		<td>178</td>
		<td>12</td>
		<td>—</td>
		<td>—</td>
		<td>166</td>
	</tr>
	<tr>
		<td>Other (j)</td>
		<td>271</td>
		<td>7</td>
		<td>—</td>
		<td>—
</td>
		<td>264</td>
	</tr>
	<tr>
		<td></td>
		<td>$ 9,717</td>
		<td>$ 2,878</td>
		<td>$ 724</td>
		<td>$ 4</td>
		<td>$ 6,111</td>
	</tr>
	<tr>
		<td>December 31, 2016:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Equities:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>U.S. large cap (a)</td>
		<td>$ 1,889</td>
		<td>$ 1,284</td>
		<td>$ —</td>
		<td>$ —</td>
		<td>$ 605</td>
	</tr>
	<tr>
		<td>U.S. mid and small cap (b)</td>
		<td>549</td>
		<td>183</td>
		<td>—
</td>
		<td>—
</td>
		<td>366</td>
	</tr>
	<tr>
		<td>International (c)</td>
		<td>1,345</td>
		<td>356</td>
		<td>—
</td>
		<td>—
</td>
		<td>989</td>
	</tr>
	<tr>
		<td>Fixed income securities:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>U.S. government securities (d)</td>
		<td>437</td>
		<td>5</td>
		<td>258</td>
		<td>—</td>
		<td>174</td>
	</tr>
	<tr>
		<td>Corporate debt instruments (e)</td>
		<td>813</td>
		<td>100</td>
		<td>348</td>
		<td>—
</td>
		<td>365</td>
	</tr>
	<tr>
		<td>Non-U.S. government securities (f)</td>
		<td>514</td>
		<td>175</td>
		<td>—</td>
		<td>—
</td>
		<td>339</td>
	</tr>
	<tr>
		<td>Other (g)</td>
		<td>183</td>
		<td>80</td>
		<td>20</td>
		<td>—</td>
		<td>83</td>
	</tr>
	<tr>
		<td>Absolute return funds (h)</td>
		<td>1,891</td>
		<td>106</td>
		<td>—</td>
		<td>—
</td>
		<td>1,785</td>
	</tr>
	<tr>
		<td>Commodities (i)</td>
		<td>84</td>
		<td>—</td>
		<td>—
</td>
		<td>12</td>
		<td>72</td>
	</tr>
	<tr>
		<td>Cash and Cash Equivalents</td>
		<td>100</td>
		<td>8</td>
		<td>—</td>
		<td>—</td>
		<td>92</td>
	</tr>
	<tr>
		<td>Other (j)</td>
		<td>153</td>
		<td>—</td>
		<td>—
</td>
		<td>—
</td>
		<td>153</td>
	</tr>
	<tr>
		<td></td>
		<td>$ 7,958</td>
		<td>$ 2,297</td>
		<td>$ 626</td>
		<td>$ 12</td>
		<td>$ 5,023</td>
	</tr>
</table>
<p>(a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.</p>
<p>(b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices.</p>
<p>(c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.</p>
<p style="font-size: small; color: grey;"><i>83</i></p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>

</body>
</html>
